RxDoctor Payments DataLook up a doctor →

Wayne Fujita, MD

Dermatology · Aiea, HINPI 1073690152

Payments from drug & device makers

$385,218in general payments, 2019–2025

Across 1,652 payments — averaging $233.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$79K
  • AbbVie$77K
  • Amgen$74K
  • E.r. Squibb & Sons, L.L.C.$32K
  • Galderma Laboratories, L.p.$28K
  • Bristol Myers Squibb$26K
  • plus $68K from 27 others

What the payments were for

  • Consulting fees$69,91418%
  • Speaking & faculty fees$241,95563%
  • Travel & lodging$29,1938%
  • Food & beverage$43,22011%
  • Education$9350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$385,218 in reported general payments places this provider in the 95th percentile of 67 dermatology providers in Hawaii.

See all dermatology providers in Hawaii

Medicare billing

Part B allowed, 2024
$170,414
Medicare patients
463
Services billed
1,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab51$189,988
OtezlaApremilast12$58,277
OpzeluraRuxolitinib Phosphate22$44,233
Tacrolimus130$36,540
VtamaTapinarof11$15,344
Tazarotene34$7,930
Ammonium Lactate398$6,775
Tretinoin66$4,781
Fluocinonide63$3,837
Ketoconazole293$3,524
Fluorouracil56$2,917
Fluocinonide-EFluocinonide/Emollient Base41$2,621
Calcipotriene12$2,544
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc83$2,164
Imiquimod56$1,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$74,196$58,27712 claims
Incyte CorporationOpzelura$1,530$44,23322 claims
Dermavant Sciences, Inc.Vtama$610$15,34411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 67 dermatology providers in Hawaii.

Other dermatology in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →